A nanofibrous sheet-based system for linear delivery of nifedipine

Park, Chun Gwon; Kim, Eunji; Park, Min; Park, Jung Hwan; Choy, Young Bin

doi:10.1016/j.jconrel.2010.10.023

Cited by 34 publications

(13 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Resultssupporting

confidence: 90%

“…Compared with PLGA MS and PLGA/PEG MS, the retention of PLGA NM showed significant differences at 12, 18, 24 and 36 h ( P < 0.05). This considerable improvement in sinonasal retention may be attributed to synergistically improved mucoadhesiveness due to the enlarged specific surface area originating from the nanostructure192021; thus, the PLGA/PEG NM used here better adhered to the mucosal layer in the sinonasal space.…”

Section: Resultsmentioning

confidence: 96%

“…The MS prepared by the conventional emulsion method exhibited a spherical shape and a smooth surface, whereas the NM showed a rough nanofibrous surface192021. The overall morphologies of the MS and NM were not influenced by the presence of PEG, RSV or DTTCI, in accordance with our previous study192021. Here, the MS and NM were prepared so that they possessed a similar size distribution, which was measured to be 6.72–7.64 μm (Figure S2 and Table S1 in the Supplementary Information).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Sinonasal Delivery of Resveratrol via Mucoadhesive Nanostructured Microparticles in a Nasal Polyp Mouse Model

Lee

Park

Huh

et al. 2017

Sci Rep

Self Cite

View full text Add to dashboard Cite

Resveratrol (RSV) has been shown to effectively suppress chronic rhinosinusitis with nasal polyps in a mouse model; however, when locally administered to the sinonasal cavity, bolus RSV is limited by low drug bioavailability owing to its low aqueous solubility and relatively rapid clearance from the administration site. To address this limitation, we propose mucoadhesive nanostructured microparticles (PLGA/PEG NM) as a potential carrier for the sinonasal delivery of RSV. In this study, PLGA/PEG NM released RSV in a sustained manner. Owing to the enlarged specific surface area of the nanostructures, PLGA/PEG NM had synergistically enhanced mucoadhesiveness and thus showed improved in vivo retention properties in the sinonasal cavity. Therefore, when tested in a mouse nasal polyp model, PLGA/PEG NM mitigated polyp formation and restored epithelial integrity better than the control treatments. The therapeutic effect was similar at half the dose of PLGA/PEG NM, suggesting improved local bioavailability of RSV in the sinonasal cavity.

show abstract

Section: Resultssupporting

confidence: 90%

Section: Resultsmentioning

confidence: 96%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Sinonasal Delivery of Resveratrol via Mucoadhesive Nanostructured Microparticles in a Nasal Polyp Mouse Model

Lee

Park

Huh

et al. 2017

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…[47][48][49] Basit bir elektro-çekim düzeneği yüksek voltaj güç kaynağı, besleme ünitesi ve toplama kısımlarından oluşmaktadır (Şekil 1).…”

Section: Elektro-çeki̇m (Electrospi̇nni̇ng) Yöntemi̇ni̇n Nanoli̇f Ve Yara öunclassified

Wound Healing and Electrospun Wound Dressings: Review

Tort¹,

Acartürk²

2015

Turkiye Klinikleri J Pharm Sci

View full text Add to dashboard Cite

“…At the same time, OROS® suffers from certain limitations that generally limit all oral delivery systems, namely poor delivery of peptides and proteins. In addition, the localized drug release has been shown to cause GI irritation and ulcers [85], though such issues have been relatively rare [86]. …”

Section: Introductionmentioning

confidence: 99%

An overview of clinical and commercial impact of drug delivery systems

Anselmo¹,

Mitragotri²

2014

Journal of Controlled Release

395

215

View full text Add to dashboard Cite

Drug delivery systems are widely researched and developed to improve the delivery of pharmaceutical compounds and molecules. The last few decades have seen a marked growth of the field fueled by increased number of researchers, research funding, venture capital and the number of start-ups. Collectively, the growth has led to novel systems that make use of micro/nano-particles, transdermal patches, inhalers, drug reservoir implants and antibody-drug conjugates. While the increased research activity is clearly an indication of proliferation of the field, clinical and commercial translation of early-stage research ideas is critically important for future growth and interest in the field. Here, we will highlight some of the examples of novel drug delivery systems that have undergone such translation. Specifically, we will discuss the developments, advantages, limitations and lessons learned from: (i) microparticle-based depot formulations, (ii) nanoparticle-based cancer drugs, (iii) transdermal systems, (iv) oral drug delivery systems, (v) pulmonary drug delivery, (vi) implants and (vii) antibody-drug conjugates. These systems have impacted treatment of many prevalent diseases including diabetes, cancer and cardiovascular diseases, among others. At the same time, these systems are integral and enabling components of products that collectively generate annual revenues exceeding US $100 billion. These examples provide strong evidence of the clinical and commercial impact of drug delivery systems.

show abstract

A nanofibrous sheet-based system for linear delivery of nifedipine

Cited by 34 publications

References 32 publications

Sinonasal Delivery of Resveratrol via Mucoadhesive Nanostructured Microparticles in a Nasal Polyp Mouse Model

Sinonasal Delivery of Resveratrol via Mucoadhesive Nanostructured Microparticles in a Nasal Polyp Mouse Model

Wound Healing and Electrospun Wound Dressings: Review

An overview of clinical and commercial impact of drug delivery systems

Contact Info

Product

Resources

About